The success of an antiviral vaccine depends on its capacity to induce strong and sustained antiviral immunity. While a number of methods are employed to achieve this goal, it is still unclear whether lentiviral vectors are able to induce efficient antiviral immunity in vivo. Introduction of antigen into dendritic cells (DC) by using lentiviral vectors leads to antigen presentation and activation of virus-specific cytotoxic T lymphocytes (CTL) in vitro in human and murine models, as well as in vivo in murine tumor models (4, 5, 7, 10, 20) . However, due to rapid viral replication, the control of a viral infection in vivo requires strong T-cell responses, both qualitatively and quantitatively.
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The murine model of lymphocytic choriomeningitis virus (LCMV) infection is a well-defined system for studying protective CTL responses in vivo (1, 11, 15, 16, 19, 21) . Therefore, this experimental system is appropriate for addressing the question of whether lentiviral vectors are suitable tools for introducing antigen into DC in order to induce protective antiviral immunity in vivo.
Our study demonstrates for the first time that third-generation lentiviral vectors are capable of introducing antigen into DC, which confer a strong protective antiviral immunity in vivo.
Vaccination with LV-GFPUbigp33-transduced DC induces the expansion of antigen-specific T cells in vivo. We first asked whether LV-GFPUbigp33-transduced DC could prime LCMV glycoprotein-specific CD8 ϩ T cells in vitro and in vivo. LVGFPUbigp33 is a third-generation lentiviral vector that encodes the transgene GFPUbigp33 (immunodominant epitope of LCMV glycoprotein, positions 33 to 41 [gp33-41], fused with ubiquitin and enhanced green fluorescent protein [GFP] sequences) (17, 18) . Bone marrow-derived DC from C57BL/6 mice (IFFA-Credo, L'Arbresle, France) were generated as published previously (20) . Briefly, bone marrow cells were differentiated into DC by culturing in medium supplemented with murine granulocyte-macrophage colony stimulating factor (ImmunoKontact, Lugano, Switzerland), interleukin 4, and Flt3-L (R&D, Abingdon, United Kingdom) for 9 days. Thirdgeneration lentiviral vectors were transduced at day 3, after nonadherent cells were discarded from the culture. At day 7, DC were matured by adding 1 g/ml of lipopolysaccharide (Difco, Detroit, Mich.) in the presence of cytokines.
When DC were transduced with LV-GFPUbigp33 at a multiplicity of infection of 5, the average transduction efficiency for LV-GFPUbigp33 was 18.5% (data not shown). At the same multiplicity of infection the efficiency of transduction of DC with lentiviral vectors encoding GFP was around 35% (20) . Importantly, the design of the LV-GFPUbigp33 construct efficiently increases the capacity of transduced DC to stimulate proliferation of the CD8 ϩ T cells from transgenic mice expressing a T-cell receptor specific for LCMV gp33-41 (14) . Previously described lentiviral constructs (20) , i.e., LVLCMVgp and LV-gp33IRESGFP, encoding full-length LCMV glycoprotein and a minigene (gp33) internal ribosome entry site GFP, respectively, were less efficient in vitro and in vivo (data not shown; also, see Fig. 2 ).
After optimization for lentiviral transduction and antigen presentation, C57BL/6 mice received 10 5 DC transduced with LV-GFPUbigp33 (normalized for GFP expression) or 10 5 DC pulsed with LCMV gp33-41 or control DC. Seven days later, peripheral blood mononuclear cells were isolated and analyzed by flow cytometry for the detection of gp33-41 tetramer-positive cells among CD8 ϩ T cells (Fig. 1) . LVGFPUbigp33 induced a mean of 2.01% (standard error of the mean [SEM] ϭ 0.822) tetramer-positive cells among CD8 ϩ T cells in blood, while control LV-GFP-transduced DC gave a mean of 0.2% (SEM ϭ 0.045) (Fig. 1) . Corresponding values were 1.26% (SEM ϭ 0.227) for peptide gp33-41-pulsed DC and 0.24% (SEM ϭ 0.059) for unpulsed DC (Fig. 1) . Unlike LV-GFPUbigp33, neither LV-LCMVgp nor LV-gp33IRESGFP was able to induce tetramer-positive cells among CD8 ϩ T cells in blood (data not shown). Vaccination with LV-GFPUbigp33-transduced DC provides protection against intravenous LCMV infection in vivo. Next, we tested whether DC transduced with LV-GFPUbigp33 (10 4 DC) provide CD8-dependent protection against viral chal-lenge with LCMV by the intravenous (i.v.) route. Seven days after vaccination with DC, mice were challenged with LCMV (i.v.). Five days after the challenge, spleens were removed and LCMV titers were determined in spleen homogenates (2, 3). Mice vaccinated with 10 4 DC transduced with LV-GFPUbigp33 had average LCMV titers that were 4 logs lower than those for mice that received 10 4 DC encoding an irrelevant protein (GFP) or mice treated with unpulsed DC (10 4 ) (P Ͻ 0.0005) (Fig. 2) . Protection against an i.v. challenge with LCMV was similar in mice vaccinated with 10 4 DC transduced with LVGFPUbigp33 and in those vaccinated with 10 4 DC pulsed with LCMV gp33-41. In contrast, LV-LCMVgp-and LVgp33IRESGFP-transduced DC were unable to induce protection in mice (Fig. 2) .
Vaccination with LV-GFPUbigp33-transduced DC provides complete protection against peripheral LCMV infection in vivo. We further assessed whether vaccination with DC transduced with lentiviral vectors could protect wild-type C57BL/6 mice against replication of LCMV in the footpad. Protection against viral replication in a peripheral solid organ requires not only a high frequency of LCMV glycoprotein-specific CD8 ϩ memory T cells but also a high-level activation of these memory CD8
ϩ T cells, so that they recirculate through peripheral tissues (8) . In this assay, a footpad swelling response is observed in naïve and incompletely protected animals as a consequence of local immune response to LCMV, whereas fully protected animals do not show such a reaction. Naïve mice were injected i.v. with 10 5 DC transduced with LV-GFPUbigp33 (normalized with GFP expression). Seven days later, vaccinated mice were challenged with 10 3 PFU of LCMV (Armstrong) in the footpads as described previously (6, 9, 12) . While 10 5 DC pulsed with peptide induced swelling on day 4 and 5, 10 5 DC transduced with LV-gp33IRESGFP caused no detectable footpad swelling (Fig. 3) . Control DC or DC transduced with LV-GFP ( 10 5 ) showed maximal swelling at day 7 to 8. The P value for DC transduced with LVgp33IRESGFP compared with DC transduced with LV-GFP was calculated from day 7 to 10 and was highly significant (P ϭ 0.001). Mice rendered immune by infection with LCMV (200 PFU, WE strain) 7 days prior to footpad infection showed also no detectable footpad swelling (9) . Together, these results indicate that DC transduced with LV-gp33IRESGFP confer full protection against peripheral challenge with LCMV (no swelling), while DC pulsed with LCMV gp33-41 incompletely protect the animals (partial swelling on days 5 and 6; P ϭ 0.05 compared with DC transduced with LV-gp33IRESGFP).
Our study firmly establishes that lentiviral vector-mediated transduction of DC leads to induction of antiviral immunity in vivo, against both an i.v. and a peripheral viral challenge in a LCMV model. The LCMV mouse model is a well-established system for studying the efficiency of a candidate vaccine in vivo (1, 11, 15, 16, 19, 21) .
Our vaccination protocol with DC transduced with lentiviral vectors encoding LCMV gp33-41 and injected i.v. induced no footpad swelling in response to viral challenge (i.e., viral elimination) in peripheral tissue (i.e., the footpad), while peptidepulsed DC induced an early and reduced footpad swelling in our experiments. Mullins et al. (13) , using peptide-pulsed DC injected i.v., were also unable to confer protective immunity to subcutaneously implanted tumors. It thus appears that lentiviral transduction of antigen into DC may generate a more potent vaccine than pulsing DC with peptide in vivo.
Therefore, lentiviral vectors should be considered good candidates for vaccines against acute and chronic infections with viruses such as human immunodeficiency virus and hepatitis B or C virus, either by direct injection or after loading on dendritic cells. 
